Inscrição YC de Cambridge Cancer Genomics

Summer 2017Inactive

Cambridge Cancer Genomics passou pela Y Combinator no batch Summer 2017 como uma empresa Healthcare. Abaixo: o que a empresa faz, quem a fundou e sua inscrição para a YC, reconstruída pergunta por pergunta no formulário real da YC.

Batch YC: Summer 2017
Indústria: HealthcareDiagnostics
Tamanho da equipe: 25
Status: Inactive
Lançada: 2017

Fundadores

John CassidyFounder/CEO
Nirmesh PatelFounder/Chief Scientific Officer
Evaline TsaiFounder/CPO

O que Cambridge Cancer Genomics faz

CCG.ai exist to ensure that each patient has the right drug, at the right time, to beat their cancer. ‍ We build the software to enable data-driven precision oncology and systematically develop data-driven biomarkers indicative of treatment response. We believe that increasing amounts of clinical and genomic data have the potential to transform cancer treatment, and enable oncologists to make smarter decisions about which drug to use in which circumstance. We are expanding our team in Cambridge, UK, offering a fantastic opportunity for dedicated individuals who are comfortable in a high-work high-reward environment, and who are enthusiastic for a dynamic and varied role. We are looking for people who fit well into our team and company culture, and who like to overcome challenges and drive the business forward. In exchange, we offer a competitive salary with performance related bonuses and stock options, alongside excellent career development opportunities in a fast-growing start-up with a chance to truly impact how cancer is treated. To apply, please send your CV to

Inscrição YC de Cambridge Cancer Genomics, reconstruída

Inscrição Y Combinator

Cambridge Cancer Genomics, lote Summer 2017. As verdadeiras perguntas do formulário, respondidas com dados públicos.

Founders2
Company7
Progress7
Idea4
Equity3
Curious2
Batch Preference1

Company

Company name

Cambridge Cancer Genomics

Describe what your company does in 50 characters or less.

Personalized cancer treatment planning software

What is your company going to make? Please describe your product and what it does or will do.

We build software that helps oncologists interpret clinical and genomic data to pick the right drug for each cancer patient. Our platform analyzes patient biomarkers and treatment responses to guide precision oncology decisions.

Where do you live now, and where would the company be based after YC?

We currently live and work in Cambridge, England, United Kingdom, and the company remains based there.

Explain your decision regarding location.

Cambridge has the scientific and clinical expertise in genomics and oncology we need. Being close to hospitals and research centers allows faster collaboration and product validation.

21 respostas a mais na inscrição completa

Founders, Progress, Idea, Equity, Curious, Batch Preference estão na versão completa. Crie uma conta gratuita para abri-la no YC Insights, ao lado de todos os outros batches da YC.

Ver inscrição completa

Perguntas Frequentes

Esta é a inscrição real da YC de Cambridge Cancer Genomics?

Não. A Y Combinator mantém as inscrições submetidas em privado. Esta é uma reconstrução: as perguntas reais do formulário da YC, respondidas a partir dos dados públicos de Cambridge Cancer Genomics (notas de lançamento, históricos de fundadores, descrição do produto). Mostra como uma empresa como Cambridge Cancer Genomics se apresentaria à YC, não o texto que eles submeteram.

Em qual batch da YC Cambridge Cancer Genomics esteve?

Cambridge Cancer Genomics fez parte do batch Summer 2017 da Y Combinator.

Quem fundou o Cambridge Cancer Genomics?

O Cambridge Cancer Genomics foi fundado por John Cassidy, Nirmesh Patel, Evaline Tsai.

O que o Cambridge Cancer Genomics faz?

CCG.ai empowers clinicians to make personalised treatment strategies…

Como eu leio o application completo reconstruído?

Crie uma conta gratuita no Round Funded. A versão completa de 26 respostas do application do Cambridge Cancer Genomics, e de todos os outros lotes do YC, está no YC Insights.